Macquarie Asset Management acquires 100% of Genuone Sciences for KRW 620bn
- Deal value
- $428m
- Stake
- 100%
- Implied 100%
- $428m
- Revenue
- $271m
- Op. income
- $5m
- Multiples
- EQV/EBIT 92.5xPSR 1.6x
Deal value ÷ stake (structure unconfirmed)
2023 연결 · DART-verified
2023 연결 · DART-verified
On implied equity value
DART 20240422000526
- Target
- Genuone Sciences · Synthetic drug CDMO
- Buyer
- Macquarie Asset Management · 기타
- Seller
- IMM Private Equity
- Structure
- —
- Announced
- Jul 16, 2024
- Closed
- —
- Stage
- Closed
Target
Synthetic-drug CDMO formed in November 2020 from Kolmar Korea's pharma division and Kolmar Pharma, with plants in Sejong and Jecheon producing most dosage forms. As of May 2024 it held approvals for 723 products and reportedly works with more than 80% of Korean pharma companies (Dailypharm).
Deal rationale
IMM PE acquired Kolmar Korea's pharma unit and Kolmar Pharma in 2020 for KRW 451.7bn through its Rose Gold IV fund and sold about 3.5 years later at an enterprise value of KRW 750bn (incl. net debt) and 100% equity value of KRW 620bn, stating it would recover about 2x the fund's investment (Asia Economy, The Fact). Dailypharm reported analysis that Macquarie focused on the company's rapid growth and stable profitability.
| Revenue | $271m |
| Operating income | $5m |
| EBITDA | $44m |
| Net income | — |
2023 연결 · DART-verified · 20240422000526
Press coverage
- 아시아경제 (2024-07-17): “지분 100% 가치는 6200억원으로 책정됐다.”
- 더팩트 (2024-07-20): “순차입금을 포함한 기업가치는 7500억원”
- 데일리팜 (2024-05-04): “매각대금은 6200억원이다.”
- 딜사이트 (2026-01-02): “맥쿼리PE가 지난해 IMM프라이빗에쿼티(PE)로부터 제뉴원사이언스 지분 100%를 인수한 지 불과 1년 만에 진행됐다.”
This is a data entry summarising filings and press reports. Please check the original sources for the figures.